Beta blockers are associated with lower all-cause mortality among HFpEF patients.

Autor: Ibrahim J; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Fabrizio C; Division of Cardiovascular Disease, Lewis Katz Temple School of Medicine, Philadelphia, PA, USA., Sezer A; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Thoma F; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Boyle B; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Mulukutla SR; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.; Clinical Analytics, University of Pittsburgh Medical Center, Pittsburgh, PA, USA., Huston JH; Ascension Saint Thomas Heart, Nashville, TN, USA., Simon MA; Division of Cardiology, University of California San Francisco Medical Center, San Francisco, CA, USA., Hickey GW; Heart and Vascular Institute, University of Pittsburgh Medical Center, Pittsburgh, PA, USA. hickeygw@upmc.edu.
Jazyk: angličtina
Zdroj: Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2024 Jun; Vol. 113 (6), pp. 951-958. Date of Electronic Publication: 2024 May 02.
DOI: 10.1007/s00392-024-02451-0
Abstrakt: Background: The evidence regarding beta blocker (BB) benefit in heart failure with preserved ejection fraction (HFpEF) remains inconclusive, leading to consideration of BB withdrawal in this population.
Objectives: In this study, we retrospectively analyzed the association of BB on all-cause mortality in HFpEF patients.
Methods: This is a single-center retrospective cohort study of 20,206 patients with left ventricular ejection fraction (EF) ≥ 50% who were hospitalized with decompensated HF between January 2011 and March 2020. Survival is reported at 30 days, 1 year, and 3 years. A secondary analysis comparing mortality for patients on BB with additional indications including hypertension (HTN), coronary artery disease (CAD), and atrial fibrillation (AF) was completed. Mortality was compared between patients on BB and additional therapies of spironolactone or angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEi/ARBs).
Results: BB showed lower all-cause mortality at 30 days, 1 year, and 3 years (p < 0.0001). This association with lower all-cause mortality was validated by a supplementary propensity score-matched analysis. At 3 years, there was significant mortality reduction with addition of BB to either spironolactone (p = 0.0359) or ACEi/ARBs (p < 0.0001).
Conclusion: In a large single-center retrospective registry, BB use was associated with lower mortality in HFpEF patients with a recent decompensated HF hospitalization. The mortality benefit persisted in those treated with spironolactone or ACEi/ARBs, and in those with AF. This provocative data further highlights the uncertainty of the benefit of BB use in this cohort and calls for re-consideration of BB withdrawal, especially in those tolerating it well, without conclusive, large, and randomized trials showing lack of benefit or harm.
(© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: